LOS ANGELES, CA--(Marketwire -04/19/12)- In an exclusive Expert Briefing at BioMedReports, Yuichi Iwaki, M.D., Ph.D., the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV - News) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma (AEA), a long-lasting and severe form of asthma episode in which symptoms are unresponsive to initial bronchodilator or corticosteroid therapy.
Some staggering statistics show that AEA episodes account for more than 1.5 million annual emergency room visits in the U.S. alone, and no new options have been introduced in the emergency setting during the past two decades. The lack of treatment options and increasing costs represent an urgent need for innovative approaches.
MediciNova's intravenous administration of bedoradrine sulfate, a novel, highly selective beta(2)-adrenergic receptor agonist is discussed in the exclusive report which can be read at: http://www.biomedreports.com/2012041993038/a-new-approach-to-the-treatment-of-severe-asthma-episodes.html
MediciNova, a San Diego and Japan-based biopharmaceutical company, is currently testing bedoradrine sulfate (under the proprietary name MN-221) for this purpose. In late March, the company announced it had completed enrollment of 176 patients in a Phase 2 clinical trial evaluating the safety and efficacy of MN-221 for the treatment of AEA, and the company anticipates releasing clinical results in the second quarter of 2012.
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. A premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com